vs
Side-by-side financial comparison of TScan Therapeutics, Inc. (TCRX) and TOP Financial Group Ltd (TOP). Click either name above to swap in a different company.
TOP Financial Group Ltd is the larger business by last-quarter revenue ($2.9M vs $2.6M, roughly 1.1× TScan Therapeutics, Inc.). TOP Financial Group Ltd runs the higher net margin — 6.6% vs -895.1%, a 901.7% gap on every dollar of revenue.
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel T cell receptor (TCR) immunotherapies for hard-to-treat cancers. Its proprietary platform identifies high-affinity naturally occurring TCRs targeting tumor antigens, with pipeline candidates spanning hematological malignancies and solid tumors, operating in the global oncology therapeutics market.
Sun Life Financial Inc. is a Canadian financial services company headquartered in Toronto, Ontario. Founded in 1865, it operates internationally in life insurance, wealth management, and asset management. As of 2024, the company manages over CAD$1.3 trillion in assets and serves clients in Canada, the United States, Asia, and other markets.
TCRX vs TOP — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.6M | $2.9M |
| Net Profit | $-23.0M | $190.5K |
| Gross Margin | — | — |
| Operating Margin | -929.4% | — |
| Net Margin | -895.1% | 6.6% |
| Revenue YoY | 286.0% | — |
| Net Profit YoY | 35.8% | — |
| EPS (diluted) | $-0.18 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.6M | — | ||
| Q3 25 | $2.5M | $2.9M | ||
| Q2 25 | $3.1M | — | ||
| Q1 25 | $2.2M | — | ||
| Q3 24 | $1.0M | — | ||
| Q4 23 | $7.2M | — | ||
| Q3 23 | $3.9M | — | ||
| Q2 23 | $3.1M | — |
| Q4 25 | $-23.0M | — | ||
| Q3 25 | $-35.7M | $190.5K | ||
| Q2 25 | $-37.0M | — | ||
| Q1 25 | $-34.1M | — | ||
| Q3 24 | $-29.9M | — | ||
| Q4 23 | $-19.6M | — | ||
| Q3 23 | $-23.0M | — | ||
| Q2 23 | $-24.0M | — |
| Q4 25 | -929.4% | — | ||
| Q3 25 | -1475.6% | — | ||
| Q2 25 | -1256.6% | — | ||
| Q1 25 | -1669.7% | — | ||
| Q3 24 | -3109.8% | — | ||
| Q4 23 | -296.2% | — | ||
| Q3 23 | -636.7% | — | ||
| Q2 23 | -781.8% | — |
| Q4 25 | -895.1% | — | ||
| Q3 25 | -1422.1% | 6.6% | ||
| Q2 25 | -1201.3% | — | ||
| Q1 25 | -1571.9% | — | ||
| Q3 24 | -2849.1% | — | ||
| Q4 23 | -272.0% | — | ||
| Q3 23 | -591.6% | — | ||
| Q2 23 | -763.8% | — |
| Q4 25 | $-0.18 | — | ||
| Q3 25 | $-0.28 | — | ||
| Q2 25 | $-0.28 | — | ||
| Q1 25 | $-0.26 | — | ||
| Q3 24 | $-0.25 | — | ||
| Q4 23 | $0.32 | — | ||
| Q3 23 | $-0.24 | — | ||
| Q2 23 | $-0.51 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $152.4M | $14.8M |
| Total DebtLower is stronger | $32.5M | — |
| Stockholders' EquityBook value | $123.1M | $35.0M |
| Total Assets | $228.8M | $64.1M |
| Debt / EquityLower = less leverage | 0.26× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $152.4M | — | ||
| Q3 25 | $184.5M | $14.8M | ||
| Q2 25 | $218.0M | — | ||
| Q1 25 | $251.7M | — | ||
| Q3 24 | $271.1M | — | ||
| Q4 23 | $192.0M | — | ||
| Q3 23 | $215.4M | — | ||
| Q2 23 | $208.8M | — |
| Q4 25 | $32.5M | — | ||
| Q3 25 | $32.4M | — | ||
| Q2 25 | $32.3M | — | ||
| Q1 25 | $32.2M | — | ||
| Q3 24 | $30.6M | — | ||
| Q4 23 | $30.0M | — | ||
| Q3 23 | $29.9M | — | ||
| Q2 23 | $29.7M | — |
| Q4 25 | $123.1M | — | ||
| Q3 25 | $144.0M | $35.0M | ||
| Q2 25 | $176.7M | — | ||
| Q1 25 | $210.2M | — | ||
| Q3 24 | $229.1M | — | ||
| Q4 23 | $150.9M | — | ||
| Q3 23 | $169.0M | — | ||
| Q2 23 | $190.6M | — |
| Q4 25 | $228.8M | — | ||
| Q3 25 | $262.2M | $64.1M | ||
| Q2 25 | $298.6M | — | ||
| Q1 25 | $332.7M | — | ||
| Q3 24 | $348.0M | — | ||
| Q4 23 | $272.1M | — | ||
| Q3 23 | $291.4M | — | ||
| Q2 23 | $316.9M | — |
| Q4 25 | 0.26× | — | ||
| Q3 25 | 0.23× | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | 0.15× | — | ||
| Q3 24 | 0.13× | — | ||
| Q4 23 | 0.20× | — | ||
| Q3 23 | 0.18× | — | ||
| Q2 23 | 0.16× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-32.0M | — |
| Free Cash FlowOCF − Capex | $-32.2M | — |
| FCF MarginFCF / Revenue | -1253.3% | — |
| Capex IntensityCapex / Revenue | 6.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-139.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-32.0M | — | ||
| Q3 25 | $-32.5M | — | ||
| Q2 25 | $-33.3M | — | ||
| Q1 25 | $-37.6M | — | ||
| Q3 24 | $-27.9M | — | ||
| Q4 23 | $-23.8M | — | ||
| Q3 23 | $8.0M | — | ||
| Q2 23 | $-22.0M | — |
| Q4 25 | $-32.2M | — | ||
| Q3 25 | $-33.9M | — | ||
| Q2 25 | $-34.5M | — | ||
| Q1 25 | $-39.1M | — | ||
| Q3 24 | $-29.3M | — | ||
| Q4 23 | $-24.2M | — | ||
| Q3 23 | $6.6M | — | ||
| Q2 23 | $-22.4M | — |
| Q4 25 | -1253.3% | — | ||
| Q3 25 | -1349.6% | — | ||
| Q2 25 | -1123.1% | — | ||
| Q1 25 | -1801.8% | — | ||
| Q3 24 | -2792.0% | — | ||
| Q4 23 | -336.1% | — | ||
| Q3 23 | 169.7% | — | ||
| Q2 23 | -712.9% | — |
| Q4 25 | 6.7% | — | ||
| Q3 25 | 56.8% | — | ||
| Q2 25 | 41.6% | — | ||
| Q1 25 | 70.6% | — | ||
| Q3 24 | 130.6% | — | ||
| Q4 23 | 6.5% | — | ||
| Q3 23 | 36.5% | — | ||
| Q2 23 | 13.3% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
